Medtronic (MDT) Commences 2 New Trials for Symplicity RDS Evaluation
Medtronic, Inc. (NYSE: MDT) has started two clinical initiatives evaluating the broader, real-world clinical use of the company’s Symplicity renal denervation system across multiple conditions. Furthering its leadership in the development of renal denervation therapy, Medtronic launched the Global SYMPLICITY Patient Registry, which will evaluate the real-world, long-term impact of renal denervation in more than 5,000 patients, as well as SYMPLICITY-HF, the first clinical trial to examine renal denervation in patients with chronic heart failure and renal impairment.
Renal denervation therapy is a minimally invasive, catheter-based procedure that modulates the output of nerves that line the walls of the arteries leading to the kidneys. These nerves impact the sympathetic nervous system, which affects the major organs that are responsible for regulating blood pressure: the brain, the heart, the kidneys and the blood vessels.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Renal denervation therapy is a minimally invasive, catheter-based procedure that modulates the output of nerves that line the walls of the arteries leading to the kidneys. These nerves impact the sympathetic nervous system, which affects the major organs that are responsible for regulating blood pressure: the brain, the heart, the kidneys and the blood vessels.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
- Pluristem (PSTI) CEO Aberman Sends Letter to Shareholders;
- Trading Radar for 05/22: Best Buy (BBY), Dell (DELL), Qihoo 360 (QIHU), Take-Two (TTWO), AutoZone (AZO) Report
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

Down)